0.00Open0.01Pre Close0 Volume959 Open Interest100.00Strike Price0.00Turnover1464.39%IV-0.24%PremiumDec 6, 2024Expiry Date0.25Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.0183Delta0.0300Gamma9975.00Leverage Ratio-85.7073Theta0.0000Rho-182.66Eff Leverage0.0000Vega
Merck & Co Stock Discussion
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...
No comment yet